Opinion|Videos|January 8, 2024
MONARCH 3: First-Line Abemaciclib Plus Nonsteroidal AI for HR+/HER2- Advanced Breast Cancer
Experts on breast cancer review the final overall survival results from MONARCH 3 investigating abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+/HER2- advanced breast cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.
ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
Durability of PFS and OS Benefit vs. Historical Control
3
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
4
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
5